Queensland TACSGP

Queensland Translation and Commercialisation Skills Gap Program (TACSGP)

The Queensland Translation and Commercialisation Skills Gap Program is for Queensland-based biomed founders or early-stage businesses.

The program is a strategic collaboration between Brandon Capital and the Department of State Development, Infrastructure, Local Government and Planning under their Biomedical Roadmap initiative.

Program Purpose

Brandon BioCatalyst will guide a limited cohort of companies and entrepreneurs on a transformative journey that culminates in the opportunity to attend BIO2024 in San Diego (at your own expense).

Brandon BioCatalyst will work with TIQ to provide the Cohort with an opportunity to present at the Queensland Investor Roundtable event at BIO 2024.

Who Should Apply?

Queensland-based biomed founders or early-stage businesses.

If you’re developing a new human therapeutic with proprietary IP; adhering to global regulatory frameworks, and are able to attend BIO2024 in the USA in June 2024, you should take a look.

NOTE:  The Seminar series will be available to all EOI applicants, so if you are unsuccessful in obtaining one of the Cohort positions, you will still be able to benefit from the key training seminars.

Where will the program be delivered?

Translational Research Institute on the PA Hospital campus in Woolloongabba.

What to expect?

📚 A four-part seminar series covering pivotal subjects like pre-commercialization planning, early preclinical development, clinical and regulatory strategy, and company formation, investment, and partnering.

🔧 Beyond Seminars: Practical workshops exploring business planning, CUREator grants, clinical and regulatory development, and BIO preparation and planning.

🤝 You’ll have access to the globally connected Brandon BioCatalyst team, who will help you navigate the early stages of innovation, driving towards commercialization outcomes, including investment and partnerships.

Program OverviewTuesday 27 February 2024 – Preparing your Research for Tranlsation.

Therapeutic development planning, early commercialisation considerations and spin out creation. After lunch the Cohort will have a session on business planning and Target Product Profiles from a Pharmaceutical perspective presented by ex GSK VP and Head of Biology and current Brandon Capital Venture Partner  Dr Roberto Solari

Thursday 21 March 2024- Research discoveries into drug development programs.

Cover the formal pre-clinical development requirements to support translation.

Tuesday 23 April 2024 – Translating research to the Clinic

Preparing for and completing clinical development activities, including regulatory aspects and designing and conducting clinical trials.

14 May (9:00 – 10:30 session)

Briefing with the Queensland United States Commissioner.

Tuesday 7 May 2024 – Company formation, fundraising and partnering

Includes a leadership characteristics and training session

When do applications close?

Monday 11 December 5:00pm AEST

How to apply

More details about the program and how to apply can be found here.